- Home
- IMA vs IMUX Comparison
IMA vs IMUX Comparison
Compare IMA & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMA | IMUX |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | 15 | 66 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.3M | 75.2M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | IMA | IMUX |
|---|---|---|
| Price | $5.70 | $1.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $16.00 | $4.25 |
| AVG Volume (30 Days) | 30.9K | ★ 2.9M |
| Earning Date | 03-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.35 | $0.51 |
| 52 Week High | $17.50 | $1.51 |
Technical Indicators
Market Signals| Indicator | IMA | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 38.78 | 50.46 |
| Support Level | N/A | $0.64 |
| Resistance Level | $7.28 | $1.17 |
| Average True Range (ATR) | 0.41 | 0.12 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 38.17 | 6.45 |
Price Performance
Historical ComparisonAbout IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.